Saturn V Capital Management’s Sage Therapeutics SAGE Stock Holding History

Saturn V Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-70,559	Closed	-$3.32M	–	22
2023 Q2	$3.32M	Sell	70,559 -74,459	-51%	-$3.7M	1.84%	18
2023 Q1	$6.08M	Sell	145,018 -11,067	-7%	-$476K	4.54%	13
2022 Q4	$5.37M	Buy	+156,085	New	+$5.96M	4.45%	14

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Saturn V Capital Management's SAGE Position: Q3 2023 in Review

Saturn V Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 70,559 shares — an estimated $3.32M sold.

Saturn V Capital Management first reported a position in SAGE in Q4 2022 and held it in 3 quarters. The position peaked at $6.08M in Q1 2023. 194 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

Saturn V Capital Management reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
Saturn V Capital Management sold 70,559 Sage Therapeutics shares in Q3 2023, an estimated $3.32M.
Saturn V Capital Management first reported a position in Sage Therapeutics in Q4 2022 and held it in 3 quarters.
Saturn V Capital Management's Sage Therapeutics position peaked at $6.08M in Q1 2023.
194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Saturn V Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.